Login / Signup

Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.

Lucia GozzoSalvatore LeottaGiovanni Luca RomanoCalogero VetroAndrea DuminucoGiuseppe MiloneAlessandra CupriFanny Erika PalumboSerena BrancatiRosy RuscicaLaura LongoDaniela Cristina VitaleGiorgia FiorenzaGiovanni Enrico LombardoAntonio LazzaraFrancesco Di RaimondoGiuseppe Alberto Maria PalumboFilippo Drago
Published in: Journal of clinical medicine (2024)
After European Medicines Agency (EMA) approval, national pricing and reimbursement procedures are necessary to guarantee access to drugs, based on the willingness to pay and the recognition of therapeutic value. These can result in delays in drug availability for patients, even for those with important unfmet needs for whom it may be necessary and ethical to ensure access. The objective of this study was to evaluate the use of ruxolitinib for patients with graft-versus-host disease (GvHD) after EMA approval at the University Hospital of Catania. We analysed data about the use of ruxolitinib in patients with GvHD, describing their basic characteristics, their outcomes and the cost of the treatment. In the reference period, 24 ruxolitinib treatments were started according to the Summary of Product Characteristic. The average treatment duration was 10 months. Twenty patients showed a response, maintained over time, with no adverse reactions. The total expenditure amounts to EUR 963,424. The use of ruxolitinib in a real population confirms its role in an important therapeutic need. The quantification of costs requires a reflection on the sustainability of early access to medicines authorised by the EMA for serious diseases and in the absence of therapeutic alternatives.
Keyphrases